Fidaxomicin

Restricted
Restricted

C. diff Risk

None

Oral Bioavailability

NA

Approximate Cost

Dosing

Adult

C. difficile
200mg po BID x 10days

Must be approved for usage by Infectious Diseases and Pharmacy to confirm supply

Renal

No dosage adjustment required

Restricted Use

Must be approved for usage by Infectious Diseases and Pharmacy to confirm supply

General Information

Common Usage

C. difficile colitis refractory to first line therapies and/or re-infection not responding to conventional therapies.

Adverse Effects

  • ¬†GI disturbance

  • ¬†Cytopenias

  • ¬†Hypersensitivity: facial, tongue or throat swelling

Additional Information

Consult Infectious Diseases prior to usage

Pharmacology

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None